Growth Hormone Peptides: The Complete Secretagogue Guide

Growth hormone is not secreted continuously. The pituitary releases GH in discrete pulses — typically 6 to 12 per day in young adults — with the largest pulse occurring roughly 60–90 minutes after sleep onset during slow-wave sleep. This pulsatile pattern is not a quirk; it is biologically essential. Continuous GH exposure desensitises receptors and blunts downstream IGF-1 signalling. Pharmacologic strategies that try to raise GH all day long (like synthetic GH injections) are trading receptor sensitivity for peak levels, which is why research into secretagogues that preserve the pulse architecture has accelerated dramatically.

Two hypothalamic hormones govern this pulse system. Growth hormone-releasing hormone (GHRH) acts on somatotroph cells in the anterior pituitary to stimulate synthesis and release of GH. Somatostatin does the opposite — it acts as the brake. GH pulse amplitude is determined by the ratio of GHRH stimulation to somatostatin tone at any given moment. The third player is ghrelin, the gut peptide that binds a distinct receptor (GHS-R1a) and amplifies GHRH signalling through a separate but synergistic pathway. This three-signal model explains why the most effective research stacks combine a GHRH analogue with a ghrelin mimetic (GHRP): you press the accelerator and release the brake simultaneously.

Research peptides in the GH space fall into two mechanistic classes: GHRH analogues (CJC-1295 variants, Sermorelin, Tesamorelin) that bind the GHRH receptor and stimulate GH synthesis, and GHRPs — Growth Hormone Releasing Peptides — (Ipamorelin, GHRP-2, GHRP-6, Hexarelin) that act primarily at GHS-R1a. Using them together produces GH pulses 2–10× larger than either compound alone, a synergy documented in multiple Phase I and Phase II clinical trials.

The anabolic and lipolytic effects attributed to GH are largely mediated by insulin-like growth factor 1 (IGF-1), produced primarily in the liver in response to GH signalling. IGF-1 acts on muscle satellite cells to drive protein synthesis, on adipocytes to stimulate lipolysis, and on chondrocytes to support joint and connective tissue maintenance. In a healthy young adult, IGF-1 should fall in the upper-middle range for their age group; chronic low IGF-1 correlates strongly with accelerated body fat accumulation, reduced lean mass, impaired recovery, and poor sleep architecture.

Monitoring serum IGF-1 is the most practical way to gauge whether your GH peptide protocol is working. Most secretagogue protocols targeting wellness raise IGF-1 by 30–60% from baseline within 8–12 weeks. Excessively high IGF-1 (top 5% of reference range or above) is associated with potential downsides including increased IGF-1-driven cell proliferation, which is why clinical oversight and bloodwork are standard practice in research contexts. Staying within the upper-normal range is the consensus target.

Insulin and GH exist in a reciprocal relationship. Elevated insulin — from a recent carbohydrate-containing meal — suppresses GH secretion directly at the pituitary and reduces GHRH receptor sensitivity. This is why virtually all clinical GH peptide protocols specify injecting in a fasted state, defined as at least 2 hours post-meal and ideally 3+ hours. For the pre-bed injection, the standard recommendation is no food containing significant carbohydrates for 2 hours beforehand. A small amount of protein (e.g., a casein shake or chicken) appears to have minimal blunting effect.

Sleep amplifies GH secretion dramatically. The largest daily GH pulse in healthy adults coincides with sleep onset and peaks during slow-wave (stage 3) sleep. Administering a GHRH analogue or GHRP pre-bed amplifies this endogenous pulse rather than creating an artificial one in isolation. This is why even single-injection protocols almost universally target pre-sleep administration. Many users also report that GH peptides improve sleep depth and duration as a direct effect, likely through somatotroph-mediated increases in slow-wave sleep.